MetLife Investment Management’s Ginkgo Bioworks DNA Stock Holding History

MetLife Investment Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$141K	Buy	22,948 +4,479	+24%	+$37.3K	﹤0.01%	2383
2025 Q4	$153K	Sell	18,469 -5,778	-24%	-$62.2K	﹤0.01%	2405
2025 Q3	$354K	Hold	24,247	–	–	﹤0.01%	1989
2025 Q2	$273K	Buy	+24,247	New	+$188K	﹤0.01%	2014
2024 Q2	–	Sell	-915	Closed	-$42.5K	–	2891
2024 Q1	$42.5K	Buy	915 +13	+1%	+$673	﹤0.01%	2729
2023 Q4	$61K	Sell	902 -5	-0.6%	-$306	﹤0.01%	2758
2023 Q3	$65.6K	Buy	907 +2	+0.2%	+$160	﹤0.01%	2784
2023 Q2	$67.4K	Buy	905 +287	+46%	+$17K	﹤0.01%	2858
2023 Q1	$32.9K	Buy	618 +2	+0.3%	+$127	﹤0.01%	2748
2022 Q4	$41.7K	Buy	616 +22	+4%	+$2.02K	﹤0.01%	2775
2022 Q3	$74.1K	Sell	594 -8	-1%	-$953	﹤0.01%	2731
2022 Q2	$57.3K	Buy	+602	New	+$73.4K	﹤0.01%	2800

Other funds holding DNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MetLife Investment Management's DNA Position: Q1 2026 in Review

MetLife Investment Management increased its Ginkgo Bioworks (DNA) stake by 24% in Q1 2026, buying an estimated $37.3K and bringing the position to 22,948 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #2383.

MetLife Investment Management first reported a position in DNA in Q2 2022 and has held it in 12 quarters since. The position peaked at $354K in Q3 2025. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

MetLife Investment Management held 22,948 shares of Ginkgo Bioworks worth $141K as of Q1 2026.
MetLife Investment Management bought 4,479 Ginkgo Bioworks shares in Q1 2026, an estimated $37.3K.
Ginkgo Bioworks made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2383 holding.
MetLife Investment Management first reported a position in Ginkgo Bioworks in Q2 2022 and has held it in 12 quarters since.
MetLife Investment Management's Ginkgo Bioworks position peaked at $354K in Q3 2025.
174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.